Lv47
750 积分 2025-05-03 加入
Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort
3天前
已完结
Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine
18天前
已完结
Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update
18天前
已完结
A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population
18天前
已完结
ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy
3个月前
已完结
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer
3个月前
已完结
Efficacy of osimertinib resumption with dabrafenib and trametinib for elderly patients with EGFR-mutated lung adenocarcinoma harboring acquired BRAF V600E resistant mutation resistant to osimertinib
3个月前
已关闭
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial
3个月前
已完结
Brief Report: Osimertinib Plus Capmatinib for Patients with MET-Altered EGFR-Mutant NSCLC following progression on front line therapy
3个月前
已完结
Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients
4个月前
已完结
皖公网安备34019202002308
